Palatin Technologies, Inc. (PTN)
- Previous Close
1.7200 - Open
1.7200 - Bid 1.7100 x 1100
- Ask 1.7500 x 1100
- Day's Range
1.7028 - 1.7500 - 52 Week Range
1.4300 - 5.6500 - Volume
17,433 - Avg. Volume
689,079 - Market Cap (intraday)
27.836M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9800 - Earnings Date May 14, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.33
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
palatin.comRecent News: PTN
Performance Overview: PTN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTN
Valuation Measures
Market Cap
27.76M
Enterprise Value
19.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.99
Price/Book (mrq)
--
Enterprise Value/Revenue
2.69
Enterprise Value/EBITDA
-0.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-84.77%
Return on Equity (ttm)
-1,413.30%
Revenue (ttm)
7.1M
Net Income Avi to Common (ttm)
-35.04M
Diluted EPS (ttm)
-2.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
9.49M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.03M